Cargando…

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia

Hyperkalemia is a potentially life-threatening condition, and patients who have chronic kidney disease, who are diabetic, or who are taking renin–angiotensin–aldosterone system inhibitors are at increased risk. Therapeutic options for hyperkalemia tend to have limited effectiveness and can be associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lingyun, Harrison, Stephen D., Cope, M. Jamie, Park, Craig, Lee, Lawrence, Salaymeh, Faleh, Madsen, Deidre, Benton, Wade W., Berman, Lance, Buysse, Jerry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976659/ https://www.ncbi.nlm.nih.gov/pubmed/26856345 http://dx.doi.org/10.1177/1074248416629549

Ejemplares similares

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Pharmacodynamic effects of the K(+) binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats
por: Iyer, Sai Prasad N., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
por: Colbert, Gates, et al.
Publicado: (2022)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2021)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
por: Beccari, Mario V, et al.
Publicado: (2017)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
Publicado: (2019)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Patiromer in a Patient with Severe Hyperkalemia on Incremental Hemodialysis with 1 Session per Week: A Case Report and Literature Review
por: De La Flor, José C., et al.
Publicado: (2021)

Gut Microbiota and Host Cometabolism Are Altered by Patiromer-Induced Changes in Serum and Stool Potassium
por: Gao, Bei, et al.
Publicado: (2020)

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

A curious case of persistently relapsing hyperkalemia in an ESRD patient on maintenance hemodialysis following bioprosthetic aortic valve replacement – a potential case for the use of the new agent, patiromer, for hyperkalemia management
por: Onuigbo, Macaulay Amechi Chukwukadibia, et al.
Publicado: (2016)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective
por: Fischer, Barbara, et al.
Publicado: (2022)

Piecing Together the Potassium Puzzle: The Weak Association Between Dietary Potassium and Hyperkalemia
por: Joshi, Shivam, et al.
Publicado: (2023)

Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
por: Pinnell, Derek, et al.
Publicado: (2022)

Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure
por: Patel, Shardool, et al.
Publicado: (2023)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial
por: Jaques, David A, et al.
Publicado: (2022)

The Colon as the Potassium Target: Entering the Colonic Age of Hyperkalemia Treatment?
por: Batlle, Daniel, et al.
Publicado: (2015)

Intractable hyperkalemia due to nicorandil induced potassium channel syndrome
por: Chowdhry, Vivek, et al.
Publicado: (2015)

Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients
por: Plantaz, Milan M. E. A., et al.
Publicado: (2020)

Selective potassium uptake via biocompatible zeolite–polymer hybrid microbeads as promising binders for hyperkalemia
por: Wang, Zhoujun, et al.
Publicado: (2020)

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
por: Bhattarai, Shreeyukta, et al.
Publicado: (2019)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Hyperkalemia caused by rapid red cell transfusion and the potassium absorption filter
por: Imashuku, Yasuhiko, et al.
Publicado: (2017)

Comparison of Nonabsorbable and Absorbable Suture in Total Knee Arthroplasty
por: Liu, Shuguang, et al.
Publicado: (2018)

An effective nonabsorbable suture technique for distal clavicle fractures
por: Polat, Abdulkadir, et al.
Publicado: (2022)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant
por: Schnelle, Kendra, et al.
Publicado: (2020)

Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
por: Krogager, Maria Lukács, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rererujca1b685qovu0dhc8hmd